STA-9090 for Treatment of AML, CML, MDS and Myeloproliferative Disorders

Inclusion Criteria * Males and females 18 years or older * Eligible subjects must have one of the following relapsed or refractory hematologic malignancies: AML, MDS, CML, or myeloproliferative disorders as defined in the protocol * Must have acceptable organ function during screening as defined in the protocol Exclusion Criteria * Pregnant or breast-feeding women * Patients must meet the washout periods for prior chemotherapies and radiation * History of stroke within 6 months of treatment * Poor venous access for study drug administration * Treatment with chronic immunosuppressants * Other severe acute/chronic medical or psychiatric condition, or laboratory abnormality that may increase the risk associated with study participation